Effects of mydriatic agents in cockatoos, African gray parrots, and Blue-fronted Amazon parrots

Jan C. Ramer, Joanne R Paul-Murphy, David Brunson, Christopher J Murphy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: To compare, in psittacines, the mydriatic effects of several topically applied curariform, sympathomimetic, and parasympatholytic drugs with and without the addition of surface-acting penetrating agents. Design: Prospective, randomized controlled trial. Animals: 10 adult cockatoos (Cacatua sulphurea subspecies), 2 adult African gray parrots (Psittacus erithacus), and 3 adult Blue-fronted Amazon parrots (Amazona aestiva). Procedure: Three curariform drugs (d-tubocurarine, pancuronium, and vecuronium bromide) and 2 autonomic drugs (atropine and phenylephrine hydrochloride) were evaluated. Drugs were tested with and without the addition of a surface-acting penetrating agent, either saponin or benzalkonium chloride. The agent that resulted in the most significant change in pupillary diameter with the fewest systemic side effects in the cockatoos then was evaluated for its effects in the African gray parrots and the Blue-fronted Amazon parrots. During each drug trial, 1 eye was randomly selected to receive the control drug (0.9% NaCl), and the opposite eye was selected to receive the test drug. Each pupil was videotaped 5 (cockatoos only), 15, 30, 45, 60, and 75 minutes after treatment. Pupil diameters were measured by use of a computerized image analysis system. Data for pupil size were analyzed by means of repeated measures ANOVA. Results: Vecuronium without the addition of a surface-acting penetrating agent produced the most consistent and greatest pupillary dilatation in all 3 species with the fewest systemic side effects. Clinical Implications: Vecuronium is potentially a clinically useful, topical mydriatic agent for use in avian species. Documented differences in the prevalence of systemic side effects between species suggests that caution should be applied when applying this drug bilaterally.

Original languageEnglish (US)
Pages (from-to)227-230
Number of pages4
JournalJournal of the American Veterinary Medical Association
Volume208
Issue number2
StatePublished - Jan 15 1996
Externally publishedYes

Fingerprint

Cockatoos
Amazona
Parrots
Mydriatics
parrots
Vecuronium Bromide
Pupil
Neuromuscular Nondepolarizing Agents
drugs
Pharmaceutical Preparations
Psittaciformes
Autonomic Agents
Benzalkonium Compounds
Pancuronium
Tubocurarine
Parasympatholytics
Sympathomimetics
students
Drug and Narcotic Control
adverse effects

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Effects of mydriatic agents in cockatoos, African gray parrots, and Blue-fronted Amazon parrots. / Ramer, Jan C.; Paul-Murphy, Joanne R; Brunson, David; Murphy, Christopher J.

In: Journal of the American Veterinary Medical Association, Vol. 208, No. 2, 15.01.1996, p. 227-230.

Research output: Contribution to journalArticle

@article{8e9bd9b017fa43aaab91513f9da46600,
title = "Effects of mydriatic agents in cockatoos, African gray parrots, and Blue-fronted Amazon parrots",
abstract = "Objective: To compare, in psittacines, the mydriatic effects of several topically applied curariform, sympathomimetic, and parasympatholytic drugs with and without the addition of surface-acting penetrating agents. Design: Prospective, randomized controlled trial. Animals: 10 adult cockatoos (Cacatua sulphurea subspecies), 2 adult African gray parrots (Psittacus erithacus), and 3 adult Blue-fronted Amazon parrots (Amazona aestiva). Procedure: Three curariform drugs (d-tubocurarine, pancuronium, and vecuronium bromide) and 2 autonomic drugs (atropine and phenylephrine hydrochloride) were evaluated. Drugs were tested with and without the addition of a surface-acting penetrating agent, either saponin or benzalkonium chloride. The agent that resulted in the most significant change in pupillary diameter with the fewest systemic side effects in the cockatoos then was evaluated for its effects in the African gray parrots and the Blue-fronted Amazon parrots. During each drug trial, 1 eye was randomly selected to receive the control drug (0.9{\%} NaCl), and the opposite eye was selected to receive the test drug. Each pupil was videotaped 5 (cockatoos only), 15, 30, 45, 60, and 75 minutes after treatment. Pupil diameters were measured by use of a computerized image analysis system. Data for pupil size were analyzed by means of repeated measures ANOVA. Results: Vecuronium without the addition of a surface-acting penetrating agent produced the most consistent and greatest pupillary dilatation in all 3 species with the fewest systemic side effects. Clinical Implications: Vecuronium is potentially a clinically useful, topical mydriatic agent for use in avian species. Documented differences in the prevalence of systemic side effects between species suggests that caution should be applied when applying this drug bilaterally.",
author = "Ramer, {Jan C.} and Paul-Murphy, {Joanne R} and David Brunson and Murphy, {Christopher J}",
year = "1996",
month = "1",
day = "15",
language = "English (US)",
volume = "208",
pages = "227--230",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "2",

}

TY - JOUR

T1 - Effects of mydriatic agents in cockatoos, African gray parrots, and Blue-fronted Amazon parrots

AU - Ramer, Jan C.

AU - Paul-Murphy, Joanne R

AU - Brunson, David

AU - Murphy, Christopher J

PY - 1996/1/15

Y1 - 1996/1/15

N2 - Objective: To compare, in psittacines, the mydriatic effects of several topically applied curariform, sympathomimetic, and parasympatholytic drugs with and without the addition of surface-acting penetrating agents. Design: Prospective, randomized controlled trial. Animals: 10 adult cockatoos (Cacatua sulphurea subspecies), 2 adult African gray parrots (Psittacus erithacus), and 3 adult Blue-fronted Amazon parrots (Amazona aestiva). Procedure: Three curariform drugs (d-tubocurarine, pancuronium, and vecuronium bromide) and 2 autonomic drugs (atropine and phenylephrine hydrochloride) were evaluated. Drugs were tested with and without the addition of a surface-acting penetrating agent, either saponin or benzalkonium chloride. The agent that resulted in the most significant change in pupillary diameter with the fewest systemic side effects in the cockatoos then was evaluated for its effects in the African gray parrots and the Blue-fronted Amazon parrots. During each drug trial, 1 eye was randomly selected to receive the control drug (0.9% NaCl), and the opposite eye was selected to receive the test drug. Each pupil was videotaped 5 (cockatoos only), 15, 30, 45, 60, and 75 minutes after treatment. Pupil diameters were measured by use of a computerized image analysis system. Data for pupil size were analyzed by means of repeated measures ANOVA. Results: Vecuronium without the addition of a surface-acting penetrating agent produced the most consistent and greatest pupillary dilatation in all 3 species with the fewest systemic side effects. Clinical Implications: Vecuronium is potentially a clinically useful, topical mydriatic agent for use in avian species. Documented differences in the prevalence of systemic side effects between species suggests that caution should be applied when applying this drug bilaterally.

AB - Objective: To compare, in psittacines, the mydriatic effects of several topically applied curariform, sympathomimetic, and parasympatholytic drugs with and without the addition of surface-acting penetrating agents. Design: Prospective, randomized controlled trial. Animals: 10 adult cockatoos (Cacatua sulphurea subspecies), 2 adult African gray parrots (Psittacus erithacus), and 3 adult Blue-fronted Amazon parrots (Amazona aestiva). Procedure: Three curariform drugs (d-tubocurarine, pancuronium, and vecuronium bromide) and 2 autonomic drugs (atropine and phenylephrine hydrochloride) were evaluated. Drugs were tested with and without the addition of a surface-acting penetrating agent, either saponin or benzalkonium chloride. The agent that resulted in the most significant change in pupillary diameter with the fewest systemic side effects in the cockatoos then was evaluated for its effects in the African gray parrots and the Blue-fronted Amazon parrots. During each drug trial, 1 eye was randomly selected to receive the control drug (0.9% NaCl), and the opposite eye was selected to receive the test drug. Each pupil was videotaped 5 (cockatoos only), 15, 30, 45, 60, and 75 minutes after treatment. Pupil diameters were measured by use of a computerized image analysis system. Data for pupil size were analyzed by means of repeated measures ANOVA. Results: Vecuronium without the addition of a surface-acting penetrating agent produced the most consistent and greatest pupillary dilatation in all 3 species with the fewest systemic side effects. Clinical Implications: Vecuronium is potentially a clinically useful, topical mydriatic agent for use in avian species. Documented differences in the prevalence of systemic side effects between species suggests that caution should be applied when applying this drug bilaterally.

UR - http://www.scopus.com/inward/record.url?scp=0030031264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030031264&partnerID=8YFLogxK

M3 - Article

VL - 208

SP - 227

EP - 230

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 2

ER -